Cipla, a leading pharmaceutical company, is actively pursuing acquisitions and strategic partnerships in the US market while simultaneously strengthening its presence in the domestic market across various segments. Based in Mumbai, the company is also focused on enhancing its revenue in Europe and improving margins in South Africa. According to Ashish Adukia, the Global Chief Financial Officer of Cipla, the company’s priorities for the US market include launching products through delisting strategies, as well as pursuing inorganic partnerships and acquisitions. Adukia emphasized the importance of commercial execution of existing portfolios and addressing observations from the US Food and Drug Administration (USFDA).
In the South African market, Cipla aims to capitalize on its performance by leveraging growth opportunities in private and select tender businesses, with a strong focus on expanding margins. Similarly, in emerging markets and Europe, the company aims to boost its revenue while maintaining sustainable margins. Adukia highlighted that the fourth quarter typically experiences weaker seasonality in India and North America.
Regarding the domestic business, Adukia emphasized the importance of strengthening growth drivers, particularly in the wellness portfolio. Cipla’s Managing Director and CEO, Umang Vohra, underscored the company’s commitment to mitigating risks associated with key launches and addressing regulatory issues across manufacturing plants, with a particular focus on resolving concerns at facilities in Goa and Indore.
Vohra mentioned that the company had responded to queries from the USFDA and is now concentrating on remediation efforts. In the October-December quarter, Cipla reported total revenue from operations of Rs 6,604 crore, marking a significant increase compared to Rs 5,810 crore in the same period last year. The company’s consolidated net profit also saw a notable rise of 32 percent, reaching Rs 1,056 crore for the December quarter compared to Rs 801 crore in the corresponding period last year.